Biopharma financings in 2023 – at $49.3 billion raised through the third quarter (Q3) – are tracking ahead of, or only slightly behind, several years since 2011, except for the two outlier years of 2020 and 2021 when there was a flurry of investments in response to the COVID-19 pandemic.
China is pushing to increase biopharma investment to woo foreign investors, and the State Council laid out policy areas to further incentivize foreign companies to expand their operations in the country. Among those policies are guaranteeing equal treatment of foreign-invested enterprises and domestic enterprises, particularly in government procurement activities.
Microsure BV recently secured €38 million (US$40 million) in a series B2 funding round that will allow it to finalize the development of its microsurgical robot, the Musa-3. The robot system is designed to give microsurgeons the precision, stability and control that are currently beyond human capabilities. “We want to make a super microsurgeon from every microsurgeon,” Sjaak Deckers, CEO of Microsure, told BioWorld.
RSS
